Byetta vs Victoza

Byetta (exenatide) and Victoza (liraglutide) are both earlier-generation GLP-1 receptor agonists approved for type 2 diabetes. Byetta, approved in 2005, requires twice-daily injections administered within 60 minutes before meals. Victoza, approved in 2010, is injected once daily at any time regardless of meals. Both medications work by mimicking the incretin hormone GLP-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying.

The LEAD-6 trial directly compared liraglutide 1.8 mg once daily to exenatide 10 mcg twice daily over 26 weeks. Liraglutide demonstrated superior HbA1c reduction (1.12% vs 0.79%) and was associated with less nausea, particularly after the initial weeks of treatment. Weight loss was similar between the two groups in that study. The once-daily dosing of Victoza, combined with its modestly stronger glycemic effect, has generally positioned it as the preferred option over Byetta in clinical practice.

Both medications share common GLP-1 class side effects including nausea, vomiting, and diarrhea, though these tend to diminish over time. Victoza carries an additional FDA-approved indication for reducing cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease, based on the LEADER trial -- a distinction Byetta does not hold. While both of these older agents have largely been superseded by newer weekly GLP-1 options like semaglutide and tirzepatide, they may still be encountered in clinical settings. Patients currently taking either medication should discuss with their healthcare provider whether transitioning to a newer agent might be appropriate.